Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 25

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 25
---
 financial statements; |

| • |     | discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results; |

| • |     | developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; |

| • |     | approving insurance coverage for our officers and directors; reviewing and approving related-person transactions; |

| • |     | preparing the audit committee report to be included in our annual proxy statement, reviewing with management our consolidated financial statements to be included in our quarterly reports to be filed with the SEC and reviewing with management the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosures in our periodic reports filed with the SEC; |

| • |     | overseeing financial, accounting, financial statement, and cybersecurity risk exposures and the steps that management has taken to monitor and control such exposures; |

| • |     | approving, or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm. |

All audit and non-auditservices, other than de minimis non-auditservices, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. Our audit committee operates under a written charter that satisfies the applicable Nasdaq listing rules and is available at https://investors.sionnatx.com/corporate-governance/documents-charters. Compensation Committee Joanne Louise Viney, Ph.D., Bruce Booth, D.Phil., Lucian Iancovici, M.D. and Laurie Stelzer, M.B.A. serve on the compensation committee, which is chaired by Dr. Viney. Our board of directors has determined that each member of the compensation committee is “independent” as defined in the applicable Nasdaq rules. The compensation committee was established in June 2024. During the fiscal year ended December 31, 2024, the compensation committee met once. The compensation committee’s responsibilities include:

| • |     | annually reviewing and recommending to our board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer; |

| • |     | evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and, based on such evaluation, recommending to our board of directors the compensation of our Chief Executive Officer, including cash and equity compensation; |

17

| • |